Significance: Nuclear factor erythroid 2 (NFE2)-related factor 2 (NFE2L2, or NRF2) is a transcription factor predominantly affecting the expression of antioxidant genes. NRF2 plays a significant role in the control of redox balance, which is crucial in cancer cells. NRF2 activation regulates numerous cancer hallmarks, including metabolism, cancer stem cell characteristics, tumor aggressiveness, invasion, and metastasis formation. We review the molecular characteristics of the NRF2 pathway and discuss its interactions with the cancer hallmarks previously listed. Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway are involved in carcinogenesis. Further, cancer-related changes (e.g., metabolic flexibility) that support cancer progression were found to be redox- and NRF2 dependent. Critical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2 are context dependent and essentially based on the specific molecular characteristics of the cancer in question. Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes. Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the activity of the NRF2 system. Future Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2 pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system interferes with cytostatic drugs and their combinations.

Department of Medical Chemistry Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Mitochondrial Physiology Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Faculty of Medicine Research Center for Molecular Medicine University of Debrecen Debrecen Hungary

MTA DE Lendület Laboratory of Cellular Metabolism Debrecen Hungary

See more in PubMed

A RE, El-Mesery M, El-Karef A, and Eissa LA. Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-beta1 expression in hepatocellular carcinoma-induced in rats. Can J Physiol Pharmacol 96: 1218–1225, 2018 PubMed

Abbas K, Breton J, Planson AG, Bouton C, Bignon J, Seguin C, Riquier S, Toledano MB, and Drapier JC. Nitric oxide activates an Nrf2/sulfiredoxin antioxidant pathway in macrophages. Free Radic Biol Med 51: 107–114, 2011 PubMed

Abu-Alainin W, Gana T, Liloglou T, Olayanju A, Barrera LN, Ferguson R, Campbell F, Andrews T, Goldring C, Kitteringham N, Park BK, Nedjadi T, Schmid MC, Slupsky JR, Greenhalf W, Neoptolemos JP, and Costello E. UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis. J Pathol 238: 423–433, 2016 PubMed PMC

Ahmad F, Dixit D, Sharma V, Kumar A, Joshi SD, Sarkar C, and Sen E. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death Dis 7: e2213, 2016 PubMed PMC

Ahn B, Pharaoh G, Premkumar P, Huseman K, Ranjit R, Kinter M, Szweda L, Kiss T, Fulop G, Tarantini S, Csiszar A, Ungvari Z, and Van Remmen H. Nrf2 deficiency exacerbates age-related contractile dysfunction and loss of skeletal muscle mass. Redox Biol 17: 47–58, 2018 PubMed PMC

Akdemir B, Nakajima Y, Inazawa J, and Inoue J. miR-432 induces NRF2 stabilization by directly targeting KEAP1. Mol Cancer Res 15: 1570–1578, 2017 PubMed

Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, and Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 274: 26071–26078, 1999 PubMed

Ali D, Mohammad DK, Mujahed H, Jonson-Videsater K, Nore B, Paul C, and Lehmann S. Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells. Br J Haematol 174: 117–126, 2016 PubMed

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, and Garcia-Blanco MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9: 997–1007, 2011 PubMed PMC

Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, and Pacher P. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 11: 505–508, 2004 PubMed

Bai X, Chen Y, Hou X, Huang M, and Jin J. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev 48: 541–567, 2016 PubMed

Bala A and Panditharadyula SS. Role of nuclear factor erythroid 2-related factor 2 (NRF-2) mediated antioxidant response on the synergistic antitumor effect of L-arginine and 5-fluro uracil (5FU) in breast adenocarcinoma. Curr Pharm Des 25: 1643–1652, 2019 PubMed

Banerjee P, Basu A, Datta D, Gasser M, Waaga-Gasser AM, and Pal S. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J Biol Chem 286: 33580–33590, 2011 PubMed PMC

Bao L, Wu J, Dodson M, Rojo de la Vega EM, Ning Y, Zhang Z, Yao M, Zhang DD, Xu C, and Yi X. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Mol Carcinog 56: 1543–1553, 2017 PubMed PMC

Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX, Yao M, Zhang DD, and Yi XF. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol 7: 1502–1513, 2014 PubMed PMC

Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, la Torre A, Balsamo T, Poeta ML, Marangi GF, Maiello E, Castelvetere M, Pellegrini F, Murgo R, Fazio VM, and Parrella P. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 8: 105–112, 2013 PubMed PMC

Barrera LN, Rushworth SA, Bowles KM, and MacEwan DJ. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle 11: 2248–2252, 2012 PubMed PMC

Bekele RT, Venkatraman G, Liu RZ, Tang X, Mi S, Benesch MG, Mackey JR, Godbout R, Curtis JM, McMullen TP, and Brindley DN. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance. Sci Rep 6: 21164, 2016 PubMed PMC

Benito A, Polat IH, Noe V, Ciudad CJ, Marin S, and Cascante M. Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. Oncotarget 8: 106693–106706, 2017 PubMed PMC

Bialk P, Wang Y, Banas K, and Kmiec EB. Functional gene knockout of NRF2 increases chemosensitivity of human lung cancer A549 cells in vitro and in a xenograft mouse model. Mol Ther Oncolytics 11: 75–89, 2018 PubMed PMC

Bocci F, Tripathi SC, Vilchez Mercedes SA, George JT, Casabar JP, Kin Wong P, Hanash SM, Levine H, Onuchic JN, and Kumar Jolly M. NRF2 activates a partial epithelial-mesenchymal transition and is maximally present in a hybrid epithelial/mesenchymal phenotype. Integr Biol 11: 251–263, 2019 PubMed PMC

This reference has been deleted

Bollong MJ, Lee G, Coukos JS, Yun H, Zambaldo C, Chang JW, Chin EN, Ahmad I, Chatterjee AK, Lairson LL, Schultz PG, and Moellering RE. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature 562: 600–604, 2018 PubMed PMC

Brewer AC, Mustafi SB, Murray TVA, Rajasekaran NS, and Benjamin IJ. Reductive stress linked to small HSPs, G6PD, and Nrf2 pathways in heart disease. Antioxid Redox Signal 18: 1114–1127, 2013 PubMed PMC

Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, Tang X, Zheng N, Major MB, and Moon RT. Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein. J Biol Chem 287: 6539–6550, 2012 PubMed PMC

Casero RA, Murray Stewart T, and Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer 18: 681–695, 2018 PubMed PMC

Chang CW, Chen YS, Tsay YG, Han CL, Chen YJ, Yang CC, Hung KF, Lin CH, Huang TY, Kao SY, Lee TC, and Lo JF. ROS-independent ER stress-mediated NRF2 activation promotes warburg effect to maintain stemness-associated properties of cancer-initiating cells. Cell Death Dis 9: 194, 2018 PubMed PMC

Chen C, Jiang X, Gu S, and Zhang Z. MicroRNA-155 regulates arsenite-induced malignant transformation by targeting Nrf2-mediated oxidative damage in human bronchial epithelial cells. Toxicol Lett 278: 38–47, 2017 PubMed

Chen F, Wang H, Zhu J, Zhao R, Xue P, Zhang Q, Bud Nelson M, Qu W, Feng B, and Pi J. Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br J Cancer 117: 1495–1506, 2017 PubMed PMC

Chen PH, Smith TJ, Wu J, Siesser PF, Bisnett BJ, Khan F, Hogue M, Soderblom E, Tang F, Marks JR, Major MB, Swarts BM, Boyce M, and Chi JT. Glycosylation of KEAP1 links nutrient sensing to redox stress signaling. EMBO J 36: 2233–2250, 2017 PubMed PMC

Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, and Zhang DD. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34: 663–673, 2009 PubMed PMC

Cheng K-C, Lin R-J, Cheng J-Y, Wang S-H, Yu J-C, Wu J-C, Liang Y-J, Hsu H-M, Yu J, and Yu AL. FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding. EBioMedicine 45: 25–38, 2019 PubMed PMC

Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Ohlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H, Hammell M, Crawford HC, Schmidt EE, Thompson CB, Pappin DJ, Sonenberg N, and Tuveson DA. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166: 963–976, 2016 PubMed PMC

Cho JM, Manandhar S, Lee HR, Park HM, and Kwak MK. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 260: 96–108, 2008 PubMed

Choi J, Kim E-S, and Koo JS. Expression of pentose phosphate pathway-related proteins in breast cancer. Dis Markers 2018: 9369358, 2018 PubMed PMC

This reference has been deleted

Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, and Hayes JD. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32: 3765–3781, 2013 PubMed PMC

Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS, Parker JS, Li J, Powers S, Kim H, Fischer S, Guindi M, Ghanekar A, and Chiang DY. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58: 1693–1702, 2013 PubMed PMC

Cong ZX, Wang HD, Zhou Y, Wang JW, Pan H, Zhang DD, Zhang L, and Zhu L. Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells. J Neurooncol 116: 41–48, 2014 PubMed

Cullinan SB and Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem 279: 20108–20117, 2004 PubMed

Cullinan SB, Gordan JD, Jin J, Harper JW, and Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24: 8477–8486, 2004 PubMed PMC

Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, and Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23: 7198–7209, 2003 PubMed PMC

Daga M, Pizzimenti S, Dianzani C, Cucci MA, Cavalli R, Grattarola M, Ferrara B, Scariot V, Trotta F, and Barrera G. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression. Phytomedicine 56: 156–164, 2019 PubMed

Danilovic DLS, de Mello ES, Frazzato EST, Wakamatsu A, de Lima Jorge AA, Hoff AO, and Marui S. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: activation of antioxidative pathway in papillary thyroid carcinoma. Head Neck 40: 1271–1278, 2018 PubMed

Das J, Sarkar A, and Sil PC. Hexavalent chromium induces apoptosis in human liver (HepG2) cells via redox imbalance. Toxicol Rep 2: 600–608, 2015 PubMed PMC

Davies KJA and Forman HJ. Does Bach1 & c-Myc dependent redox dysregulation of Nrf2 & adaptive homeostasis decrease cancer risk in ageing? Free Radic Biol Med 134: 708–714, 2019 PubMed PMC

This reference has been deleted

Davila A, Liu L, Chellappa K, Redpath P, Nakamaru-Ogiso E, Paolella LM, Zhang Z, Migaud ME, Rabinowitz JD, and Baur JA. Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. Elife 7: 33246, 2018 PubMed PMC

Davila-Gonzalez D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, and Chang JC. Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple-negative breast cancer. Clin Cancer Res 24: 1152–1162, 2018 PubMed

De Francesco EM, Sotgia F, and Lisanti MP. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochem J 475: 1611–1634, 2018 PubMed PMC

DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, and Cantley LC. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 47: 1475–1481, 2015 PubMed PMC

DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, and Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106–109, 2011 PubMed PMC

Diaz-Ruiz A, Di Francesco A, Carboneau BA, Levan SR, Pearson KJ, Price NL, Ward TM, Bernier M, de Cabo R, and Mercken EM. Benefits of caloric restriction in longevity and chemical-induced tumorigenesis are transmitted independent of NQO1. J Gerontol A Biol Sci Med Sci 74: 155–162, 2019 PubMed PMC

Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99: 11908–11913, 2002 PubMed PMC

Dodson M, Castro-Portuguez R, and Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol 11: 101107, 2019 PubMed PMC

Dong J, Li Y, Xiao H, Luo D, Zhang S, Zhu C, Jiang M, Cui M, Lu L, and Fan S. Cordycepin sensitizes breast cancer cells toward irradiation through elevating ROS production involving Nrf2. Toxicol Appl Pharmacol 364: 12–21, 2019 PubMed

Duong HQ, Yi YW, Kang HJ, Hong YB, Tang W, Wang A, Seong YS, and Bae I. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol 44: 959–969, 2014 PubMed PMC

Eades G, Yang M, Yao Y, Zhang Y, and Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 286: 40725–40733, 2011 PubMed PMC

Eggler AL, Liu G, Pezzuto JM, van Breemen RB, and Mesecar AD. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci U S A 102: 10070–10075, 2005 PubMed PMC

Eskiocak U, Kim SB, Roig AI, Kitten E, Batten K, Cornelius C, Zou YS, Wright WE, and Shay JW. CDDO-Me protects against space radiation-induced transformation of human colon epithelial cells. Radiat Res 174: 27–36, 2010 PubMed

Fabrizio FP, Costantini M, Copetti M, la Torre A, Sparaneo A, Fontana A, Poeta L, Gallucci M, Sentinelli S, Graziano P, Parente P, Pompeo V, De Salvo L, Simone G, Papalia R, Picardo F, Balsamo T, Flammia GP, Trombetta D, Pantalone A, Kok K, Paranita F, Muscarella LA, and Fazio VM. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget 8: 11187–11198, 2017 PubMed PMC

Fan Z, Wirth AK, Chen D, Wruck CJ, Rauh M, Buchfelder M, and Savaskan N. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 6: e371, 2017 PubMed PMC

Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, and Shimada M. Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction. Cell Commun Signal 16: 54, 2018 PubMed PMC

Fetoni AR, Paciello F, Mezzogori D, Rolesi R, Eramo SL, Paludetti G, and Troiani D. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer 113: 1434–1444, 2015 PubMed PMC

Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, Gajer P, Ravel J, and Goedert JJ. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med 10: 253, 2012 PubMed PMC

Fodor T, Szanto M, Abdul-Rahman O, Nagy L, Der A, Kiss B, and Bai P. Combined treatment of MCF-7 cells with AICAR and methotrexate, arrests cell cycle and reverses Warburg metabolism through AMP-activated protein kinase (AMPK) and FOXO1. PLoS One 11: e0150232, 2016 PubMed PMC

Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J, and Goedert JJ. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab 99: 4632–4640, 2014 PubMed PMC

Fulop GA, Kiss T, Tarantini S, Balasubramanian P, Yabluchanskiy A, Farkas E, Bari F, Ungvari Z, and Csiszar A. Nrf2 deficiency in aged mice exacerbates cellular senescence promoting cerebrovascular inflammation. Geroscience 40: 513–521, 2018 PubMed PMC

Furfaro AL, Piras S, Domenicotti C, Fenoglio D, De Luigi A, Salmona M, Moretta L, Marinari UM, Pronzato MA, Traverso N, and Nitti M. Role of Nrf2, HO-1 and GSH in neuroblastoma cell resistance to bortezomib. PLoS One 11: e0152465, 2016 PubMed PMC

Furfaro AL, Piras S, Passalacqua M, Domenicotti C, Parodi A, Fenoglio D, Pronzato MA, Marinari UM, Moretta L, Traverso N, and Nitti M. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib. Biochim Biophys Acta 1842: 613–622, 2014 PubMed

Fuse Y and Kobayashi M. Conservation of the Keap1-Nrf2 system: an evolutionary journey through stressful space and time. Molecules 22: pii: , 2017 PubMed PMC

Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen P-H, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, and Heymach JV. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. Cancer Res 79: 3251–3267, 2019 PubMed PMC

Garrido P, Shalaby A, Walsh EM, Keane N, Webber M, Keane MM, Sullivan FJ, Kerin MJ, Callagy G, Ryan AE, and Glynn SA. Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget 8: 80568–80588, 2017 PubMed PMC

Gill JG, Piskounova E, and Morrison SJ. Cancer, oxidative stress, and metastasis. Cold Spring Harb Symp Quant Biol 81: 163–175, 2016 PubMed

Girotti AW. Upregulation of nitric oxide in tumor cells as a negative adaptation to photodynamic therapy. Lasers Surg Med 50: 590–598, 2018 PubMed

Goedert JJ, Hua X, Bielecka A, Okayasu I, Milne GL, Jones GS, Fujiwara M, Sinha R, Wan Y, Xu X, Ravel J, Shi J, Palm NW, and Feigelson HS. Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. Br J Cancer 23: 435, 2018 PubMed PMC

Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, Falk RT, Gail MH, Shi J, Ravel J, and Feigelson HS. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst 107: pii: , 2015 PubMed PMC

Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, Daemen A, Bakalarski CE, Holcomb T, Shames DS, Hartmaier RJ, Chmielecki J, Seshagiri S, Gentleman R, and Stokoe D. Recurrent loss of NFE2L2 Exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep 16: 2605–2617, 2016 PubMed

Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, and Mak TW. Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proc Natl Acad Sci U S A 111: 4472–4477, 2014 PubMed PMC

Gorrini C, Harris IS, and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12: 931–947, 2013 PubMed

Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouze E, Calvo F, and Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694–698, 2012 PubMed PMC

Habib E, Linher-Melville K, Lin H-X, and Singh G. Expression of xCT and activity of system xc− are regulated by NRF2 in human breast cancer cells in response to oxidative stress. Redox Biol 5: 33, 2015 PubMed PMC

Hamada S, Shimosegawa T, Taguchi K, Nabeshima T, Yamamoto M, and Masamune A. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma. Am J Physiol Gastrointest Liver Physiol 314: G65–G74, 2018 PubMed

Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, Ishiguro A, Kijima H, Mimura J, Itoh K, Fukuda S, and Saijo Y. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 12: 66, 2012 PubMed PMC

Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646–674, 2011 PubMed

Hart PC, Ratti BA, Mao M, Ansenberger-Fricano K, Shajahan-Haq AN, Tyner AL, Minshall RD, and Bonini MG. Caveolin-1 regulates cancer cell metabolism via scavenging Nrf2 and suppressing MnSOD-driven glycolysis. Oncotarget 7: 308–322, 2016 PubMed PMC

Hartikainen JM, Tengstrom M, Winqvist R, Jukkola-Vuorinen A, Pylkas K, Kosma VM, Soini Y, and Mannermaa A. KEAP1 genetic polymorphisms associate with breast cancer risk and survival outcomes. Clin Cancer Res 21: 1591–1601, 2015 PubMed

Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, Wakabayashi N, Fujii J, Myers A, and Biswal S. Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46: 443–453, 2009 PubMed PMC

Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, Hayes DN, and Major MB. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res 73: 2199–2210, 2013 PubMed PMC

Hawkes HJ, Karlenius TC, and Tonissen KF. Regulation of the human thioredoxin gene promoter and its key substrates: a study of functional and putative regulatory elements. Biochim Biophys Acta 1840: 303–314, 2014 PubMed

Hayden A, Douglas J, Sommerlad M, Andrews L, Gould K, Hussain S, Thomas GJ, Packham G, and Crabb SJ. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol Oncol 32: 806–814, 2014 PubMed

Hayes JD and Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39: 199–218, 2014 PubMed

He X and Ma Q. NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation. Mol Pharmacol 76: 1265–1278, 2009 PubMed PMC

He X and Ma Q. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol Exp Ther 332: 66–75, 2010 PubMed PMC

Hegedus C, Kovacs K, Polgar Z, Regdon Z, Szabo E, Robaszkiewicz A, Forman HJ, Martner A, and Virag L. Redox control of cancer cell destruction. Redox Biol 16: 59–74, 2018 PubMed PMC

Heinze I, Bens M, Calzia E, Holtze S, Dakhovnik O, Sahm A, Kirkpatrick JM, Szafranski K, Romanov N, Sama SN, Holzer K, Singer S, Ermolaeva M, Platzer M, Hildebrandt T, and Ori A. Species comparison of liver proteomes reveals links to naked mole-rat longevity and human aging. BMC Biol 16: 82, 2018 PubMed PMC

Helleman J, Smid M, Jansen MP, van der Burg ME, and Berns EM. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 117: 170–176, 2010 PubMed

Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, and Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med 25: 377–388, 2019 PubMed

Higgins LG, Kelleher MO, Eggleston IM, Itoh K, Yamamoto M, and Hayes JD. Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents. Toxicol Appl Pharmacol 237: 267–280, 2009 PubMed

Hiramoto K, Satoh H, Suzuki T, Moriguchi T, Pi J, Shimosegawa T, and Yamamoto M. Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis. Cancer Prev Res (Phila) 7: 835–844, 2014 PubMed

Hirotsu Y, Katsuoka F, Funayama R, Nagashima T, Nishida Y, Nakayama K, Engel JD, and Yamamoto M. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res 40: 10228–10239, 2012 PubMed PMC

Hojo T, Maishi N, Towfik AM, Akiyama K, Ohga N, Shindoh M, Hida Y, Minowa K, Fujisawa T, and Hida K. ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells. Oncotarget 8: 45484–45495, 2017 PubMed PMC

Hu XF, Yao J, Gao SG, Wang XS, Peng XQ, Yang YT, and Feng XS. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. Asian Pac J Cancer Prev 14: 5231–5235, 2013 PubMed

Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, and Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 69: 1279–1283, 2009 PubMed PMC

Hussong M, Borno ST, Kerick M, Wunderlich A, Franz A, Sultmann H, Timmermann B, Lehrach H, Hirsch-Kauffmann M, and Schweiger MR. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Dis 5: e1195, 2014 PubMed PMC

Ichimura Y, Waguri S, Sou Y-S, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee M-S, Yoshimori T, Tanaka K, Yamamoto M, and Komatsu M. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 51: 618–631, 2013 PubMed

Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M, Lee MS, Tanaka K, and Komatsu M. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 193: 275–284, 2011 PubMed PMC

Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76–86, 1999 PubMed PMC

Ivan J, Major E, Sipos A, Kovacs K, Horvath D, Tamas I, Bay P, Dombradi V, and Lontay B. The short-chain fatty acid propionate inhibits adipogenic differentiation of human chorion-derived mesenchymal stem cells through the free fatty acid receptor 2. Stem Cells Dev 26: 1724–1733, 2017 PubMed PMC

Jain AK and Jaiswal AK. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J Biol Chem 292: 2051, 2017 PubMed PMC

Jana S, Patra K, Jana J, Mandal DP, and Bhattacharjee S. Nrf-2 transcriptionally activates P21(Cip/WAF1) and promotes A549 cell survival against oxidative stress induced by H2O2. Chem Biol Interact 285: 59–68, 2018 PubMed

Jayakumar S, Pal D, and Sandur SK. Nrf2 facilitates repair of radiation induced DNA damage through homologous recombination repair pathway in a ROS independent manner in cancer cells. Mutat Res 779: 33–45, 2015 PubMed

Jeong Y, Hoang NT, Lovejoy A, Stehr H, Newman AM, Gentles AJ, Kong W, Truong D, Martin S, Chaudhuri A, Heiser D, Zhou L, Say C, Carter JN, Hiniker SM, Loo BW Jr., West RB, Beachy P, Alizadeh AA, and Diehn M.. Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov 7: 86–101, 2017 PubMed PMC

Ji X, Qian J, Rahman SMJ, Siska PJ, Zou Y, Harris BK, Hoeksema MD, Trenary IA, Heidi C, Eisenberg R, Rathmell JC, Young JD, and Massion PP. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene 37: 5007–5019, 2018 PubMed PMC

Jia Y, Chen J, Zhu H, Jia ZH, and Cui MH. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes. Oncol Rep 34: 2296–2304, 2015 PubMed

Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, and Zhang DD. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 70: 5486–5496, 2010 PubMed PMC

Jiang X, Bao Y, Liu H, Kou X, Zhang Z, Sun F, Qian Z, Lin Z, Li X, Liu X, Jiang L, and Yang Y. VPS34 stimulation of p62 phosphorylation for cancer progression. Oncogene 36: 6850–6862, 2017 PubMed PMC

Jones GS, Spencer Feigelson H, Falk RT, Hua X, Ravel J, Yu G, Flores R, Gail MH, Shi J, Xu X, and Goedert JJ. Mammographic breast density and its association with urinary estrogens and the fecal microbiota in postmenopausal women. PLoS One 14: e0216114, 2019 PubMed PMC

Joo JC, Hwang JH, Jo E, Kim YR, Kim DJ, Lee KB, Park SJ, and Jang IS. Cordycepin induces apoptosis by caveolin-1-mediated JNK regulation of Foxo3a in human lung adenocarcinoma. Oncotarget 8: 12211–12224, 2017 PubMed PMC

Joo MS, Kim WD, Lee KY, Kim JH, Koo JH, and Kim SG. AMPK facilitates nuclear accumulation of Nrf2 by phosphorylating at serine 550. Mol Cell Biol 36: 1931–1942, 2016 PubMed PMC

Ju HQ, Gocho T, Aguilar M, Wu M, Zhuang ZN, Fu J, Yanaga K, Huang P, and Chiao PJ. Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation. Mol Cancer Ther 14: 788–798, 2015 PubMed

Jung BJ, Yoo HS, Shin S, Park YJ, and Jeon SM. Dysregulation of NRF2 in cancer: from molecular mechanisms to therapeutic opportunities. Biomol Ther (Seoul) 26: 57–68, 2018 PubMed PMC

Kabaria S, Choi DC, Chaudhuri AD, Jain MR, Li H, and Junn E. MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression. Free Radic Biol Med 89: 548–556, 2015 PubMed PMC

Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, Grisham MB, Mann GE, Moore K, Roberts LJ 2nd, and Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med 52: 1–6, 2012 PubMed PMC

Kang KA, Piao MJ, Kim KC, Kang HK, Chang WY, Park IC, Keum YS, Surh YJ, and Hyun JW. Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis 5: e1183, 2014 PubMed PMC

Kang YP, Torrente L, Falzone A, Elkins CM, Liu M, Asara JM, Dibble CC, and DeNicola GM. Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. Elife 8: 45572, 2019 PubMed PMC

Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, and Deeni YY. NRF2 Regulates HER1 signaling pathway to modulate the sensitivity of ovarian cancer cells to lapatinib and erlotinib. Oxid Med Cell Longev 2017: 1864578, 2017 PubMed PMC

Kansanen E, Kuosmanen SM, Leinonen H, and Levonen AL. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 1: 45–49, 2013 PubMed PMC

Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska M, Teresiak A, Filas V, Ibbs M, Blizniak R, Luczewski L, and Lamperska K. 2D and 3D cell cultures—a comparison of different types of cancer cell cultures. Arch Med Sci 14: 910–919, 2018 PubMed PMC

Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, and Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6: 857–868, 2001 PubMed

Kawamoto Y, Nakamura Y, Naito Y, Torii Y, Kumagai T, Osawa T, Ohigashi H, Satoh K, Imagawa M, and Uchida K. Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes. J Biol Chem 275: 11291–11299, 2000 PubMed

Kawasaki Y, Okumura H, Uchikado Y, Kita Y, Sasaki K, Owaki T, Ishigami S, and Natsugoe S. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol 21: 2347–2352, 2014 PubMed

Kerins MJ, Liu P, Tian W, Mannheim W, Zhang DD, and Ooi A. Genome-wide CRISPR screen reveals autophagy disruption as the convergence mechanism that regulates the NRF2 transcription factor. Mol Cell Biol 39: pii: , 2019 PubMed PMC

Kerins MJ and Ooi A. A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci Rep 8: 12846, 2018 PubMed PMC

Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, Nelson WG, and Kong AN. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. Cancer Prev Res (Phila) 7: 1186–1197, 2014 PubMed PMC

Kiesslich T, Mayr C, and Neureiter D. NRF2: the key to tumor- and patient-dependent chemosensitivity in biliary tract cancer? EBioMedicine 49: 9–10, 2019 PubMed PMC

Kim HR, Kim S, Kim EJ, Park JH, Yang SH, Jeong ET, Park C, Youn MJ, So HS, and Park R. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 60: 47–56, 2008 PubMed

Kim MS, Lee WS, and Jin W. TrkB promotes breast cancer metastasis via suppression of Runx3 and Keap1 expression. Mol Cells 39: 258–265, 2016 PubMed PMC

Kim SB, Pandita RK, Eskiocak U, Ly P, Kaisani A, Kumar R, Cornelius C, Wright WE, Pandita TK, and Shay JW. Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation. Proc Natl Acad Sci U S A 109: E2949–E2955, 2012 PubMed PMC

Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y, and Kwak MK. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res 71: 2260–2275, 2011 PubMed

Kim WD, Kim YW, Cho IJ, Lee CH, and Kim SG. E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells. J Cell Sci 125: 1284–1295, 2012 PubMed

Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ, and Lee SH. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220: 446–451, 2010 PubMed

Kipp AP, Deubel S, Arnér ESJ, and Johansson K. Time- and cell-resolved dynamics of redox-sensitive Nrf2, HIF and NF-κB activities in 3D spheroids enriched for cancer stem cells. Redox Biol 12: 403–409, 2017 PubMed PMC

Kitamura H and Motohashi H. NRF2 addiction in cancer cells. Cancer Sci 109: 900–911, 2018 PubMed PMC

Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, and Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130–7139, 2004 PubMed PMC

Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, and Yamamoto M. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12: 213–223, 2010 PubMed

Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, and Spentzos D. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 1: 59, 2008 PubMed PMC

Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, and Cannistra SA. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 71: 5081–5089, 2011 PubMed

Kovács P, Csonka T, Kovács T, Sári Z, Ujlaki G, Sipos A, Karányi Z, Szeőcs D, Hegedűs C, Uray K, Jankó L, Kiss M, Kiss B, Laoui D, Virág L, Méhes G, Bai P, and Mikó E. Lithocholic acid, a metabolite of the microbiome, increases oxidative stress in breast cancer. Cancers (Basel) 11: pii: , 2019 PubMed PMC

Kovács T, Mikó E, Vida A, Sebő É, Toth J, Csonka T, Boratkó A, Ujlaki G, Lente G, Kovács P, Tóth D, Árkosy P, Kiss B, Méhes G, Goedert JJ, and Bai P. Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. Sci Rep 9: 1300, 2019 PubMed PMC

Kröger C, Afeyan A, Mraz J, Eaton EN, Reinhardt F, Khodor YL, Thiru P, Bierie B, Ye X, Burge CB, and Weinberg RA. Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proc Natl Acad Sci U S A 116: 7353–7362, 2019 PubMed PMC

Lacher SE, Levings DC, Freeman S, and Slattery M. Identification of a functional antioxidant response element at the HIF1A locus. Redox Biol 19: 401–411, 2018 PubMed PMC

Lam HC, Baglini CV, Lope AL, Parkhitko AA, Liu H-J, Alesi N, Malinowska IA, Ebrahimi-Fakhari D, Saffari A, Yu JJ, Pereira A, Khabibullin D, Ogorek B, Nijmeh J, Kavanagh T, Handen A, Chan SY, Asara JM, Oldham WM, Diaz-Meco MT, Moscat J, Sahin M, Priolo C, and Henske EP. p62/SQSTM1 Cooperates with hyperactive mTORC1 to regulate glutathione production, maintain mitochondrial integrity, and promote tumorigenesis. Cancer Res 77: 3255–3267, 2017 PubMed PMC

Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L, and Gyorffy B. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat 160: 439–446, 2016 PubMed

Lau A, Tian W, Whitman SA, and Zhang DD. The predicted molecular weight of Nrf2: it is what it is not. Antioxid Redox Signal 18: 91–93, 2013 PubMed PMC

Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262–270, 2008 PubMed PMC

LeBoeuf SE, Wu WL, Karakousi TR, Karadal B, Jackson SR, Davidson SM, Wong KK, Koralov SB, Sayin VI, and Papagiannakopoulos T. Activation of oxidative stress response in cancer generates a druggable dependency on exogenous non-essential amino acids. Cell Metab 31: 339–350.e4, 2020 PubMed PMC

Lee JD, Cai Q, Shu XO, and Nechuta SJ. The role of biomarkers of oxidative stress in breast cancer risk and prognosis: a systematic review of the epidemiologic literature. J Womens Health (Larchmt) 26: 467–482, 2017 PubMed PMC

Lee S, Hallis SP, Jung K-A, Ryu D, and Kwak M-K. Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells. Redox Biol 24: 101210, 2019 PubMed PMC

Leone A, Roca MS, Ciardiello C, Terranova-Barberio M, Vitagliano C, Ciliberto G, Mancini R, Di Gennaro E, Bruzzese F, and Budillon A. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Free Radic Biol Med 89: 287–299, 2015 PubMed

Levonen A-L, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, and Darley-Usmar VM. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 378: 373–382, 2004 PubMed PMC

Levy JMM, Towers CG, and Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer 17: 528–542, 2017 PubMed PMC

Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, and Maher P. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 18: 522–555, 2013 PubMed PMC

Lewis KN, Wason E, Edrey YH, Kristan DM, Nevo E, and Buffenstein R. Regulation of Nrf2 signaling and longevity in naturally long-lived rodents. Proc Natl Acad Sci U S A 112: 3722–3727, 2015 PubMed PMC

Li N, Wang M, Barajas B, Sioutas C, Williams MA, and Nel AE. Nrf2 deficiency in dendritic cells enhances the adjuvant effect of ambient ultrafine particles on allergic sensitization. J Innate Immun 5: 543–554, 2013 PubMed PMC

Li W and Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 48: 91–104, 2009 PubMed PMC

Liao H, Zhou Q, Zhang Z, Wang Q, Sun Y, Yi X, and Feng Y. NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones. Oncol Rep 27: 1918–1924, 2012 PubMed

Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, Pass HI, Bhutkar AJ, Tsirigos A, Ueberheide B, Sayin VI, Papagiannakopoulos T, and Pagano M. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell 178: 316–329.e18, 2019 PubMed PMC

Lim JKM, Delaidelli A, Minaker SW, Zhang H-F, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, Leprivier G, and Sorensen PH. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A 116: 9433–9442, 2019 PubMed PMC

Lin DC, Dinh HQ, Xie JJ, Mayakonda A, Silva TC, Jiang YY, Ding LW, He JZ, Xu XE, Hao JJ, Wang MR, Li C, Xu LY, Li EM, Berman BP, and Phillip Koeffler H. Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas. Gut 67: 1769–1779, 2018 PubMed PMC

Lin P, Ren Y, Yan X, Luo Y, Zhang H, Kesarwani M, Bu J, Zhan D, Zhou Y, Tang Y, Zhu S, Xu W, Zhou X, Mei C, Ma L, Ye L, Hu C, Azam M, Ding W, Jin J, Huang G, and Tong H. The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. Haematologica 104: 485–496, 2019 PubMed PMC

Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP, Goldring CE, and Park BK. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 10: 37, 2011 PubMed PMC

Liu C, Zhao Y, Wang J, Yang Y, Zhang Y, Qu X, Peng S, Yao Z, Zhao S, He B, Mi Q, Zhu Y, Liu X, Zou J, Zhang X, and Du Q. FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. Cancer Lett 470: 29–42, 2020 PubMed

Liu T, Jiang L, Tavana O, and Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res 79: 1913–1924, 2019 PubMed PMC

Liu X, Abe-Kanoh N, Liu Y, Zhu B, Munemasa S, Nakamura T, Murata Y, and Nakamura Y. Inhibition of phosphatidylinositide 3-kinase impairs the benzyl isothiocyanate-induced accumulation of autophagic molecules and Nrf2 in human colon cancer cells. Biosci Biotechnol Biochem 81: 2212–2215, 2017 PubMed

Lodi M, Priksz D, Fulop GA, Bodi B, Gyongyosi A, Nagy L, Kovacs A, Kertesz AB, Kocsis J, Edes I, Csanadi Z, Czuriga I, Kisvarday Z, Juhasz B, Lekli I, Bai P, Toth A, Papp Z, and Czuriga D. Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy. J Transl Med 17: 229, 2019 PubMed PMC

Lu BC, Li J, Yu WF, Zhang GZ, Wang HM, and Ma HM. Elevated expression of Nrf2 mediates multidrug resistance in CD133(+) head and neck squamous cell carcinoma stem cells. Oncol Lett 12: 4333–4338, 2016 PubMed PMC

Lu K, Alcivar AL, Ma J, Foo TK, Zywea S, Mahdi A, Huo Y, Kensler TW, Gatza ML, and Xia B. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Res 77: 2881–2892, 2017 PubMed PMC

Luo L, Chen Y, Wu D, Shou J, Wang S, Ye J, Tang X, and Wang XJ. Butylated hydroxyanisole induces distinct expression patterns of Nrf2 and detoxification enzymes in the liver and small intestine of C57BL/6 mice. Toxicol Appl Pharmacol 288: 339–348, 2015 PubMed

Luo M, Shang L, Brooks MD, Jiagge E, Zhu Y, Buschhaus JM, Conley S, Fath MA, Davis A, Gheordunescu E, Wang Y, Harouaka R, Lozier A, Triner D, McDermott S, Merajver SD, Luker GD, Spitz DR, and Wicha MS. Targeting breast cancer stem cell state equilibrium through modulation of redox signaling. Cell Metab 28: 69–86, 2018 PubMed PMC

Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta M, Cheung KL, Ganesan S, Kong AN, Zhang DD, and Xia B. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol 32: 1506–1517, 2012 PubMed PMC

Ma X, Zhang J, Liu S, Huang Y, Chen B, and Wang D. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother Pharmacol 69: 485–494, 2012 PubMed

Mabley JG, Pacher P, Bai P, Wallace R, Goonesekera S, Virag L, Southan GJ, and Szabo C. Suppression of intestinal polyposis in Apcmin/+ mice by targeting the nitric oxide or poly(ADP-ribose) pathways. Mutat Res 548: 107–116, 2004 PubMed

Magesh S, Chen Y, and Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev 32: 687–726, 2012 PubMed PMC

Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, Scheffer GL, Chan JY, Manautou JE, Chen Y, Dalton TP, Yamamoto M, and Klaassen CD. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 46: 1597–1610, 2007 PubMed

Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, Shyr C, Wakabayashi N, Kensler TW, Wasserman WW, and Biswal S. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38: 5718–5734, 2010 PubMed PMC

Martinez VD, Vucic EA, Pikor LA, Thu KL, Hubaux R, and Lam WL. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer. Mol Cancer 12: 124, 2013 PubMed PMC

Martinez VD, Vucic EA, Thu KL, Pikor LA, Hubaux R, and Lam WL. Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer. Biomed Res Int 2014: 159459, 2014 PubMed PMC

Mato JM and Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 45: 1306–1312, 2007 PubMed

McMahon M, Lamont DJ, Beattie KA, and Hayes JD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A 107: 18838–18843, 2010 PubMed PMC

McMahon M, Thomas N, Itoh K, Yamamoto M, and Hayes JD. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem 279: 31556–31567, 2004 PubMed

McMahon M, Thomas N, Itoh K, Yamamoto M, and Hayes JD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a “tethering” mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 281: 24756–24768, 2006 PubMed

Menegon S, Columbano A, and Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med 22: 578–593, 2016 PubMed

Miko E, Kovacs T, Sebo E, Toth J, Csonka T, Ujlaki G, Sipos A, Szabo J, Mehes G, and Bai P. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored. Cells 8: E293, 2019 PubMed PMC

Miko E, Vida A, and Bai P. Translational aspects of the microbiome-to be exploited. Cell Biol Toxicol 32: 153–156, 2016 PubMed

Miko E, Vida A, Kovacs T, Ujlaki G, Trencsenyi G, Marton J, Sari Z, Kovacs P, Boratko A, Hujber Z, Csonka T, Antal-Szalmas P, Watanabe M, Gombos I, Csoka B, Kiss B, Vigh L, Szabo J, Mehes G, Sebestyen A, Goedert JJ, and Bai P. Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness. Biochim Biophys Acta 1859: 958–974, 2018 PubMed

Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, and Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22: 66–79, 2012 PubMed

Miura S, Shibazaki M, Kasai S, Yasuhira S, Watanabe A, Inoue T, Kageshita Y, Tsunoda K, Takahashi K, Akasaka T, Masuda T, and Maesawa C. A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance. J Invest Dermatol 134: 553–556, 2014 PubMed

Morales AA, Gutman D, Cejas PJ, Lee KP, and Boise LH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem 284: 12886–12895, 2009 PubMed PMC

Mostafavi-Pour Z, Ramezani F, Keshavarzi F, and Samadi N. The role of quercetin and vitamin C in Nrf2-dependent oxidative stress production in breast cancer cells. Oncol Lett 13: 1965–1973, 2017 PubMed PMC

Muscarella LA, Barbano R, D'Angelo V, Copetti M, Coco M, Balsamo T, la Torre A, Notarangelo A, Troiano M, Parisi S, Icolaro N, Catapano D, Valori VM, Pellegrini F, Merla G, Carella M, Fazio VM, and Parrella P. Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics 6: 317–325, 2011 PubMed PMC

Nguyen T, Sherratt PJ, Huang HC, Yang CS, and Pickett CB. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem 278: 4536–4541, 2003 PubMed

Nioi P and Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 362: 816–821, 2007 PubMed

Nioi P, Nguyen T, Sherratt PJ, and Pickett CB. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol 25: 10895–10906, 2005 PubMed PMC

Niringiyumukiza JD, Cai H, Chen L, Li Y, Wang L, Zhang M, Xu X, and Xiang W. Protective properties of glycogen synthase kinase-3 inhibition against doxorubicin-induced oxidative damage to mouse ovarian reserve. Biomed Pharmacother 116: 108963, 2019 PubMed

Numazawa S, Sugihara K, Miyake S, Tomiyama H, Hida A, Hatsuno M, Yamamoto M, and Yoshida T. Possible involvement of oxidative stress in 5-fluorouracil-mediated myelosuppression in mice. Basic Clin Pharmacol Toxicol 108: 40–45, 2011 PubMed

Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H, Sato C, and Yamamoto M. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. Proc Natl Acad Sci U S A 107: 2842–2847, 2010 PubMed PMC

Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT, and Furge KA. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 73: 2044–2051, 2013 PubMed

Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, Zhou M, Gardie B, Molinie V, Richard S, Tan PH, Teh BT, and Furge KA. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20: 511–523, 2011 PubMed

Ozgen M, Koca SS, Karatas A, Dagli AF, Erman F, Gundogdu B, Sahin K, and Isik A. Lapatinib ameliorates experimental arthritis in rats. Inflammation 38: 252–259, 2015 PubMed

Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT, and Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107: 896–904, 2003 PubMed

Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300: 862–867, 2002 PubMed

Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689–700, 2006 PubMed

Peiris-Pages M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, and Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res 18: 55, 2016 PubMed PMC

Phuong NT, Kim SK, Im JH, Yang JW, Choi MC, Lim SC, Lee KY, Kim YM, Yoon JH, and Kang KW. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells. Oncotarget 7: 13902–13916, 2016 PubMed PMC

Phuong NTT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, Ahn S-G, Yoon J-H, and Kang KW. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat 130: 73–83, 2011 PubMed

Pirpour Tazehkand A, Akbarzadeh M, Velaie K, Sadeghi MR, and Samadi N. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells. Biomed Pharmacother 103: 755–766, 2018 PubMed

Pons DG, Nadal-Serrano M, Torrens-Mas M, Valle A, Oliver J, and Roca P. UCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress. Free Radic Biol Med 86: 67–77, 2015 PubMed

Primiano T, Sutter TR, and Kensler TW. Antioxidant-inducible genes. Adv Pharmacol 38: 293–328, 1997 PubMed

Qu J, Zhang L, Li L, and Su Y. miR-148b functions as a tumor suppressor by targeting endoplasmic reticulum metallo protease 1 in human endometrial cancer cells. Oncol Res 27: 81–88, 2018 PubMed PMC

Que L, He L, Yu C, Yin W, Ma L, Cao B, and Yu S. Activation of Nrf2-ARE signaling mitigates cyclophosphamide-induced myelosuppression. Toxicol Lett 262: 17–26, 2016 PubMed

Rabinowitz JD and White E. Autophagy and metabolism. Science 330: 1344–1348, 2010 PubMed PMC

Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, and Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31: 1121–1133, 2011 PubMed PMC

Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, Tobon-Velasco JC, Devijver H, Garcia-Mayoral MF, Van Leuven F, Hayes JD, Bertho G, and Cuadrado A. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/beta-TrCP axis. Mol Cell Biol 32: 3486–3499, 2012 PubMed PMC

Ranganathan S, Krishnan A, and Sivasithambaram ND. Significance of twist and iNOS expression in human breast carcinoma. Mol Cell Biochem 412: 41–47, 2016 PubMed

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R, Berger MF, Moreira AL, Travis WD, Rudin CM, and Ladanyi M. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res 22: 3618–3629, 2016 PubMed PMC

Reuter S, Gupta SC, Chaturvedi MM, and Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49: 1603–1616, 2010 PubMed PMC

Riz I, Hawley TS, Marsal JW, Hawley RG, Riz I, Hawley TS, Marsal JW, and Hawley RG. Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget 7: 66360–66385, 2016 PubMed PMC

Rocha CR, Kajitani GS, Quinet A, Fortunato RS, and Menck CF. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget 7: 48081–48092, 2016 PubMed PMC

Roh JL, Kim EH, Jang H, and Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol 11: 254–262, 2017 PubMed PMC

Roininen N, Haapasaari KM, and Karihtala P. The role of redox-regulating enzymes in inoperable breast cancers treated with neoadjuvant chemotherapy. Oxid Med Cell Longev 2017: 2908039, 2017 PubMed PMC

Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla K, Rogowska-Wrzesinska A, Hardisson D, Serrano M, and Cuadrado A. The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal 21: 2498–2514, 2014 PubMed PMC

Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, and Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer 14: 73–80, 2007 PubMed

Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sanchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, and Papagiannakopoulos T. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23: 1362–1368, 2017 PubMed PMC

Ron D and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519–529, 2007 PubMed

Rota C, Chignell CF, and Mason RP. Evidence for free radical formation during the oxidation of 2′-7′-dichlorofluorescin to the fluorescent dye 2′-7′-dichlorofluorescein by horseradish peroxidase: possible implications for oxidative stress measurements. Free Radic Biol Med 27: 873–881, 1999 PubMed

Rushworth SA and Macewan DJ. The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers (Basel) 3: 1605–1621, 2011 PubMed PMC

Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, and MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo-resistance. Blood 120: 5188–5198, 2012 PubMed

Ryoo IG, Choi BH, Ku SK, and Kwak MK. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: implications for cancer stem cell resistance. Redox Biol 17: 246–258, 2018 PubMed PMC

Ryoo IG, Choi BH, and Kwak MK. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget 6: 8167–8184, 2015 PubMed PMC

Sadeghi MR, Jeddi F, Soozangar N, Somi MH, and Samadi N. The role of Nrf2-Keap1 axis in colorectal cancer, progression, and chemoresistance. Tumour Biol 39: 1010428317705510, 2017 PubMed

Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K, Hirose Y, Nagahashi M, Iso T, Fukutomi T, Ohishi M, Endo K, Uemura T, Nishito Y, Okuda S, Obata M, Kouno T, Imamura R, Tada Y, Obata R, Yasuda D, Takahashi K, Fujimura T, Pi J, Lee M-S, Ueno T, Ohe T, Mashino T, Wakai T, Kojima H, Okabe T, Nagano T, Motohashi H, Waguri S, Soga T, Yamamoto M, Tanaka K, and Komatsu M. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun 7: 12030, 2016 PubMed PMC

Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, Kopecka J, and Riganti C. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Mol Cancer 16: 91, 2017 PubMed PMC

Samatiwat P, Prawan A, Senggunprai L, and Kukongviriyapan V. Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 388: 601–612, 2015 PubMed

Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, Miele MM, Lailler N, Zhao C, de Stanchina E, Viale A, Akkari L, Lowe SW, Ciriello G, Hendrickson RC, and Wendel HG. The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-kinase. Cell 178: 807–819, 2019 PubMed PMC

Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, Winnard PT Jr., Raman V, Ebina M, Nukiwa T, and Yamamoto M.. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 31: 1833–1843, 2010 PubMed

Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR, Zavitsanou AM, Ubriaco J, Muir A, Karagiannis D, Morris PJ, Thomas CJ, Possemato R, Vander Heiden MG, and Papagiannakopoulos T. Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. eLife 6: pii: , 2017 PubMed PMC

Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, and Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109–113, 2009 PubMed PMC

Schatten H. Cell and Molecular Biology of Breast Cancer New York, NY: Humana Press, 2013

Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC, and Seagroves TN. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14: R6, 2012 PubMed PMC

Sekhar KR, Rachakonda G, and Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 244: 21–26, 2010 PubMed PMC

Semenza GL. Regulation of mammalian O 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551–578, 1999 PubMed

Shah NM, Rushworth SA, Murray MY, Bowles KM, and MacEwan DJ. Understanding the role of NRF2-regulated miRNAs in human malignancies. Oncotarget 4: 1130–1142, 2013 PubMed PMC

Shao J, Glorieux C, Liao J, Chen P, Lu W, Liang Z, Wen S, Hu Y, and Huang P. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo. Free Radic Res 52: 661–671, 2018 PubMed

Shi L, Wu L, Chen Z, Yang J, Chen X, Yu F, Zheng F, and Lin X. MiR-141 Activates Nrf2-dependent antioxidant pathway via down-regulating the expression of Keap1 conferring the resistance of hepatocellular carcinoma cells to 5-fluorouracil. Cell Physiol Biochem 35: 2333–2348, 2015 PubMed

Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, and Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135: 1358–1368, 2008 PubMed

Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, and Yamamoto M. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13: 864–873, 2011 PubMed PMC

Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, and Uchida K. 15-Deoxy-Δ 12,14 -prostaglandin J2. J Biol Chem 277: 10459–10466, 2002 PubMed

Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, and Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 105: 13568–13573, 2008 PubMed PMC

Shim GS, Manandhar S, Shin DH, Kim TH, and Kwak MK. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 47: 1619–1631, 2009 PubMed

Shimizu T, Inoue K, Hachiya H, Shibuya N, Aoki T, and Kubota K. Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 23: 467–471, 2016 PubMed

Shin CS, Mishra P, Watrous JD, Carelli V, D'Aurelio M, Jain M, and Chan DC. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun 8: 15074, 2017 PubMed PMC

Shirasaki K, Taguchi K, Unno M, Motohashi H, and Yamamoto M. NF-E2-related factor 2 promotes compensatory liver hypertrophy after portal vein branch ligation in mice. Hepatology 59: 2371–2382, 2014 PubMed

Sid B, Glorieux C, Valenzuela M, Rommelaere G, Najimi M, Dejeans N, Renard P, Verrax J, and Calderon PB. AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells. Biochem Pharmacol 91: 168–180, 2014 PubMed

Silva MM, Rocha CRR, Kinker GS, Pelegrini AL, and Menck CFM. The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells. Sci Rep 9: 17639, 2019 PubMed PMC

Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, and Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006 PubMed PMC

Singh B, Bhat NK, and Bhat HK. Induction of NAD(P)H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer. Carcinogenesis 33: 156–163, 2012 PubMed PMC

Singh B, Chatterjee A, Ronghe AM, Bhat NK, and Bhat HK. Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancer. BMC Cancer 13: 253, 2013 PubMed PMC

Singh B, Ronghe AM, Chatterjee A, Bhat NK, and Bhat HK. MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis 34: 1165–1172, 2013 PubMed PMC

Singh B, Shoulson R, Chatterjee A, Ronghe A, Bhat NK, Dim DC, and Bhat HK. Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogenesis 35: 1872–1880, 2014 PubMed PMC

Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, and Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274, 2006 PubMed

Sompakdee V, Prawan A, Senggunprai L, Kukongviriyapan U, Samathiwat P, Wandee J, and Kukongviriyapan V. Suppression of Nrf2 confers chemosensitizing effect through enhanced oxidant-mediated mitochondrial dysfunction. Biomed Pharmacother 101: 627–634, 2018 PubMed

Sulaiman A, McGarry S, Han X, Liu S, and Wang L. CSCs in breast cancer-one size does not fit all: therapeutic advances in targeting heterogeneous epithelial and mesenchymal CSCs. Cancers (Basel) 11: pii: , 2019 PubMed PMC

Sun X, Liu D, Xue Y, and Hu X. Enforced miR-144-3p expression as a non-invasive biomarker for the acute myeloid leukemia patients mainly by targeting NRF2. Clin Lab 63: 679–687, 2017 PubMed

Sun X, Wang S, Gai J, Guan J, Li J, Li Y, Zhao J, Zhao C, Fu L, and Li Q. SIRT5 promotes cisplatin resistance in ovarian cancer by suppressing DNA damage in a ROS-dependent manner via regulation of the Nrf2/HO-1 pathway. Front Oncol 9: 754, 2019 PubMed PMC

Sun Y, Abdul Aziz A, Bowles K, and Rushworth S. High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Cancer Lett 412: 37–45, 2018 PubMed

Suzuki T, Motohashi H, and Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34: 340–346, 2013 PubMed

Taguchi K, Hirano I, Itoh T, Tanaka M, Miyajima A, Suzuki A, Motohashi H, and Yamamoto M. Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. Mol Cell Biol 34: 900–913, 2014 PubMed PMC

Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, and Zhang DD. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res 74: 7430–7441, 2014 PubMed PMC

Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, and Hayes JD. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med 88: 108–146, 2015 PubMed PMC

Teng Y, Zhao H, Gao L, Zhang W, Shull AY, and Shay C. FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3beta-Nrf2 signaling. Cancer Res 77: 6215–6225, 2017 PubMed

Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, and Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196–5203, 2002 PubMed

Tian Y, Wu K, Liu Q, Han N, Zhang L, Chu Q, and Chen Y. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. J Hematol Oncol 9: 83, 2016 PubMed PMC

Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, van ‘t Veer LJ, Polyak K, McCormick F, and Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24: 450–465, 2013 PubMed PMC

To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, and Liby KT. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis 36: 769–781, 2015 PubMed PMC

Tonelli C, Chio IIC, and Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal 29: 1727–1745, 2018 PubMed PMC

Tong KI, Kobayashi A, Katsuoka F, and Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 387: 1311–1320, 2006 PubMed

Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, and Yamamoto M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 27: 7511–7521, 2007 PubMed PMC

Tsuji Y. JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress. Oncogene 24: 7567–7578, 2005 PubMed PMC

Ungvari Z, Tarantini S, Nyul-Toth A, Kiss T, Yabluchanskiy A, Csipo T, Balasubramanian P, Lipecz A, Benyo Z, and Csiszar A. Nrf2 dysfunction and impaired cellular resilience to oxidative stressors in the aged vasculature: from increased cellular senescence to the pathogenesis of age-related vascular diseases. Geroscience 41: 727–738, 2019 PubMed PMC

van der Wijst MG, Huisman C, Mposhi A, Roelfes G, and Rots MG. Targeting Nrf2 in healthy and malignant ovarian epithelial cells: protection versus promotion. Mol Oncol 9: 1259–1273, 2015 PubMed PMC

Venkatraman G, Benesch MG, Tang X, Dewald J, McMullen TP, and Brindley DN. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J 29: 772–785, 2015 PubMed

Venugopal R and Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17: 3145–3156, 1998 PubMed

Walker A, Singh A, Tully E, Woo J, Le A, Nguyen T, Biswal S, Sharma D, and Gabrielson E. Nrf2 signaling and autophagy are complementary in protecting breast cancer cells during glucose deprivation. Free Radic Biol Med 120: 407–413, 2018 PubMed PMC

Walsh EM, Keane MM, Wink DA, Callagy G, and Glynn SA. Review of triple negative breast cancer and the impact of inducible nitric oxide synthase on tumor biology and patient outcomes. Crit Rev Oncog 21: 333–351, 2016 PubMed PMC

Wang B, Teng Y, and Liu Q. MicroRNA-153 regulates NRF2 expression and is associated with breast carcinogenesis. Clin Lab 62: 39–47, 2016 PubMed

Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, Li Y, Li Y, Luo L, Hayes JD, Wang XJ, and Tang X. RXRalpha inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res 73: 3097–3108, 2013 PubMed

Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, Ding HF, Zhang J, Wang H, Chen X, and Yan C. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ 27: 662–675, 2020 PubMed PMC

Wang N, Song L, Xu Y, Zhang L, Wu Y, Guo J, Ji W, Li L, Zhao J, Zhang X, and Zhan L. Loss of scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. EBioMedicine 47: 65–77, 2019 PubMed PMC

Wang Q, Ma J, Lu Y, Zhang S, Huang J, Chen J, Bei JX, Yang K, Wu G, Huang K, Chen J, and Xu S. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells. Oncogene 36: 5321–5330, 2017 PubMed

Wang R, An J, Ji F, Jiao H, Sun H, and Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 373: 151–154, 2008 PubMed

Wang SW, Xu Y, Weng YY, Fan XY, Bai YF, Zheng XY, Lou LJ, and Zhang F. Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation. Food Chem Toxicol 114: 227–236, 2018 PubMed

Wang T, Liu Q, and Duan L. MBNL1 regulates resistance of HeLa cells to cisplatin via Nrf2. Biochem Biophys Res Commun 522: 763–769, 2020 PubMed

Wang XJ, Hayes JD, Henderson CJ, and Wolf CR. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci U S A 104: 19589–19594, 2007 PubMed PMC

Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J, and Tang X. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic Biol Med 70: 68–77, 2014 PubMed

Wang YY, Chen J, Liu XM, Zhao R, and Zhe H. Nrf2-mediated metabolic reprogramming in cancer. Oxid Med Cell Longev 2018: 9304091, 2018 PubMed PMC

Wang Z, Chen Z, Jiang Z, Luo P, Liu L, Huang Y, Wang H, Wang Y, Long L, Tan X, Liu D, Jin T, Wang Y, Wang Y, Liao F, Zhang C, Chen L, Gan Y, Liu Y, Yang F, Huang C, Miao H, Chen J, Cheng T, Fu X, and Shi C. Cordycepin prevents radiation ulcer by inhibiting cell senescence via NRF2 and AMPK in rodents. Nat Commun 10: 2538, 2019 PubMed PMC

Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, and Wiestner A. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res 17: 5101–5112, 2011 PubMed PMC

Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M, Yao H, Ziegler DV, Xu X, Ghosh T, Mondal T, Kanduri C, Lindahl P, Sayin VI, and Bergo MO. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell 178: 330–345, 2019 PubMed

Winkel AF, Engel CK, Margerie D, Kannt A, Szillat H, Glombik H, Kallus C, Ruf S, Gussregen S, Riedel J, Herling AW, von Knethen A, Weigert A, Brune B, and Schmoll D. Characterization of RA839, a noncovalent small molecule binder to Keap1 and selective activator of Nrf2 signaling. J Biol Chem 290: 28446–28455, 2015 PubMed PMC

Wong TF, Yoshinaga K, Monma Y, Ito K, Niikura H, Nagase S, Yamamoto M, and Yaegashi N. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival. Int J Gynecol Cancer 21: 1428–1435, 2011 PubMed

Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC, Rosenbach MD, Corr M, Schwab RB, and Carson DA. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 107: 7479–7484, 2010 PubMed PMC

Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T, Wong PK, Chapman E, Fang D, and Zhang DD. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev 28: 708–722, 2014 PubMed PMC

Wu YW, Lin CF, Lin YS, Su WC, and Chiu WH. Autophagy regulates vinorelbine sensitivity due to continued Keap1-mediated ROS generation in lung adenocarcinoma cells. Cell Death Discov 4: 33, 2018 PubMed PMC

Xia M, Yu H, Gu S, Xu Y, Su J, Li H, Kang J, and Cui M. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. Int J Oncol 45: 2341–2348, 2014 PubMed

Xiang Y, Ye W, Huang C, Yu D, Chen H, Deng T, Zhang F, Lou B, Zhang J, Shi K, Chen B, and Zhou M. Brusatol enhances the chemotherapy efficacy of gemcitabine in pancreatic cancer via the Nrf2 signalling pathway. Oxid Med Cell Longev 2018: 2360427, 2018 PubMed PMC

Xu D, Li X, Shao F, Lv G, Lv H, Lee J-H, Qian X, Wang Z, Xia Y, Du L, Zheng Y, Wang H, Lyu J, and Lu Z. The protein kinase activity of fructokinase A specifies the antioxidant responses of tumor cells by phosphorylating p62. Sci Adv 5: eaav4570, 2019 PubMed PMC

Xu X, zur Hausen A, Coy JF, and Löchelt M. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 124: 1330–1337, 2009 PubMed

Yamaguchi Y, Kamai T, Higashi S, Murakami S, Arai K, Shirataki H, and Yoshida KI. Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer. BMC Cancer 19: 1137, 2019 PubMed PMC

Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K, and Inazawa J. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer Res 12: 58–68, 2014 PubMed

Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, and Yamamoto M. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28: 2758–2770, 2008 PubMed PMC

Yang H, Huang Z-Z, Zeng Z, Chen C, Selby RR, and Lu SC. Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. Am J Physiol Gastrointest Liver Physiol 280: G184–G190, 2001 PubMed

Yang KQ, Liu Y, Huang QH, Mo N, Zhang QY, Meng QG, and Cheng JW. Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth. BMC Cancer 17: 878, 2017 PubMed PMC

Yang M, Yao Y, Eades G, Zhang Y, and Zhou Q. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res Treat 129: 983–991, 2011 PubMed PMC

Yang Y, Luo L, Cai X, Fang Y, Wang J, Chen G, Yang J, Zhou Q, Sun X, Cheng X, Yan H, Lu W, Hu C, and Cao P. Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function. Free Radic Biol Med 120: 13–24, 2018 PubMed

Yoneda K, Tanaka F, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, Kuribayashi K, Tabata C, Nakano T, and Hasegawa S. Circulating tumor cell (CTC) as a prognostic marker in primary lung cancer. J Clin Oncol 33: e22041, 2015

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, and Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 580–584, 2013 PubMed PMC

Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, Yu S, Oo KT, Ma J, and Kong AN. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol Carcinog 45: 841–850, 2006 PubMed

Yun CW and Lee SH. The roles of autophagy in cancer. Int J Mol Sci 19: pii: , 2018 PubMed PMC

Zagorski JW, Turley AE, Freeborn RA, VanDenBerg KR, Dover HE, Kardell BR, Liby KT, and Rockwell CE. Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation. Biochem Pharmacol 147: 67–76, 2018 PubMed PMC

Zhang B, Xu J, Li C, Shi S, Ji S, Xu W, Liu J, Jin K, Liang D, Liang C, Liu L, Liu C, Qin Y, and Yu X. MBD1 is an epigenetic regulator of KEAP1 in pancreatic cancer. Curr Mol Med 16: 404–411, 2016 PubMed

Zhang DD, Lo SC, Cross JV, Templeton DJ, and Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941–10953, 2004 PubMed PMC

Zhang HS, Du GY, Zhang ZG, Zhou Z, Sun HL, Yu XY, Shi YT, Xiong DN, Li H, and Huang YH. NRF2 facilitates breast cancer cell growth via HIF1a-mediated metabolic reprogramming. Int J Biochem Cell Biol 95: 85–92, 2018 PubMed

Zhang HS, Zhang ZG, Du GY, Sun HL, Liu HY, Zhou Z, Gou XM, Wu XH, Yu XY, and Huang YH. Nrf2 promotes breast cancer cell migration via up-regulation of G6PD/HIF-1alpha/Notch1 axis. J Cell Mol Med 23: 3451–3463, 2019 PubMed PMC

This reference has been deleted

Zhang J, Jiao Q, Kong L, Yu J, Fang A, Li M, and Yu J. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thorac Cancer 9: 726–735, 2018 PubMed PMC

Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, and Biswal S. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9: 336–346, 2010 PubMed PMC

Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H, Zhuang L, Chen G, Xiao Z-D, Hung M-C, Chen J, Huang P, Li W, and Gan B. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20: 1181–1192, 2018 PubMed PMC

Zhang Z, Wang Q, Ma J, Yi X, Zhu Y, Xi X, Feng Y, and Jin Z. Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via Nrf2 and HIF1alpha signaling in human epithelial ovarian cancer. Oncol Rep 29: 1429–1434, 2013 PubMed

Zhao M, Xu H, Zhang B, Hong B, Yan W, and Zhang J. Impact of nuclear factor erythroid-derived 2-like 2 and p62/sequestosome expression on prognosis of patients with gliomas. Hum Pathol 46: 843–849, 2015 PubMed

Zhou C, Zhao L, Zheng J, Wang K, Deng H, Liu P, Chen L, and Mu H. MicroRNA-144 modulates oxidative stress tolerance in SH-SY5Y cells by regulating nuclear factor erythroid 2-related factor 2-glutathione axis. Neurosci Lett 655: 21–27, 2017 PubMed

Zhou L, Ao L, Yan Y, Li C, Li W, Ye A, Liu J, Hu Y, Fang W, and Li Y. Levo-corydalmine attenuates vincristine-induced neuropathic pain in mice by upregulating the Nrf2/HO-1/CO pathway to inhibit Connexin 43 expression. Neurotherapeutics 17: 340–355, 2020 PubMed PMC

Zhou L, Zhang H, Davies KJA, and Forman HJ. Aging-related decline in the induction of Nrf2-regulated antioxidant genes in human bronchial epithelial cells. Redox Biol 14:35–40, 2018 PubMed PMC

Zhou S, Ye W, Zhang Y, Yu D, Shao Q, Liang J, and Zhang M. miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Am J Transl Res 8: 2992–3002, 2016 PubMed PMC

Zhou Z, Xu J, Bao X, Shi J, Liu B, Chen Y, and Li J. Nuclear Nrf2 activity in laryngeal carcinoma is regulated by SENP3 after cisplatin-induced reactive oxygen species stress. J Cancer 10: 3427–3434, 2019 PubMed PMC

Zhu M and Fahl WE. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem Biophys Res Commun 289: 212–219, 2001 PubMed

Zipper LM and Mulcahy RT. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 277: 36544–36552, 2002 PubMed

Biochemical Background in Mitochondria Affects 2HG Production by IDH2 and ADHFE1 in Breast Carcinoma

The Pancreatic β-Cell: The Perfect Redox System

Editorial: Epithelial-Mesenchymal Transition: Yet Another Exciting Avenue in Cancer Metabolic Remodeling